Cookson Peirce & Co. Inc. Takes Position in Neurocrine Biosciences, Inc. $NBIX

Cookson Peirce & Co. Inc. bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,271 shares of the company’s stock, valued at approximately $15,214,000. Cookson Peirce & Co. Inc. owned 0.11% of Neurocrine Biosciences as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of NBIX. Royal Bank of Canada boosted its holdings in Neurocrine Biosciences by 36.7% in the 1st quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock worth $9,158,000 after buying an additional 22,224 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Neurocrine Biosciences by 60.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock valued at $1,647,000 after purchasing an additional 5,577 shares during the period. NewEdge Advisors LLC boosted its holdings in Neurocrine Biosciences by 56.3% in the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after purchasing an additional 2,747 shares during the period. Empowered Funds LLC bought a new position in Neurocrine Biosciences in the 1st quarter valued at $1,333,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. 92.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on NBIX. Zacks Research raised shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. HC Wainwright raised their price target on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Wall Street Zen raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 25th. Citigroup raised their price target on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Canaccord Genuity Group raised their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $187.52.

Insider Buying and Selling

In related news, insider David W. Boyer sold 3,888 shares of Neurocrine Biosciences stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $156.64, for a total value of $609,016.32. Following the transaction, the insider owned 7,799 shares in the company, valued at $1,221,635.36. This trade represents a 33.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the transaction, the director owned 34,480 shares in the company, valued at approximately $5,435,772. The trade was a 30.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 328,984 shares of company stock worth $50,986,985 over the last 90 days. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $163.88 on Friday. The firm’s fifty day moving average price is $142.73 and its 200-day moving average price is $139.71. The stock has a market cap of $16.48 billion, a P/E ratio of 25.25, a price-to-earnings-growth ratio of 1.23 and a beta of 0.40. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $169.57.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.